View Ontology Report


Axitinib is a selective inhibitor of vascular endothelial growth factor (VEGF) signaling pathway used in the treatment of renal cell carcinoma and several other tumors. The drug belongs to a class of tyrosine kinase receptor inhibitors (TKI) designed to compete with ATP for binding into the ATP binding pocket of the receptor, thus inhibit its kinase activity and the signaling events downstream of it. Axitinib is selective for VEGF receptor1, 2 and 3; it can also act as a weaker inhibitor for the

Pathway Diagram:

Ariadne Genomics Inc. uptaken_axitinib ABCB1 SLCO1B1 UGT1A1 CYP3A4 CYP3A5 CYP1A2 CYP2C19 axitinib axitinib ---> uptaken_axitinib metabolized axitinib ---> axitinib and metabolites elimination axitinib and metabolites elimination UGT1A1 ---> metabolized axitinib CYP1A2 ---> metabolized axitinib CYP2C19 ---> metabolized axitinib CYP3A5 ---> metabolized axitinib CYP3A4 ---> metabolized axitinib metabolized axitinib

Genes in Pathway:

show annotations for term's descendants       view all columns           Sort by:

Pathway Gene Annotations

References Associated with the axitinib pharmacokinetics pathway:

Ontology Path Diagram:

paths to the root

Import into Pathway Studio: